To explore the effect of MTA1‐mediated MAS function on the sensitivity of cancer to clinically available anticancer drugs which may be influenced by MTA1‐mediated ATP synthase complex activity, we performed high‐throughput screening of 237 clinically validated or preclinically‐tested metabolism‐related anticancer drugs using MTA1‐KO and control cells (Figure6A). The gene discussed is MTA1; the disease is cancer.